Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialResearch in context

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialResearch in context

Summary: Background: SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CLpro) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to evaluate the efficacy and safety of SIM0417 plus ritonavir (a pharmacokinetic enhancer) in adults with COVID-19. Methods: This...

Full description

Bibliographic Details
Main Authors: Fuxiang Wang, Wen Xiao, Yimin Tang, Mengli Cao, Dan Shu, Tetsuya Asakawa, Yechun Xu, Xiangrui Jiang, Leike Zhang, Wei Wang, Jianxing Tang, Yuansheng Huang, Yang Yang, Yumei Yang, Renhong Tang, Jingshan Shen, Hongzhou Lu
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:The Lancet Regional Health. Western Pacific
Subjects:
Covid-19
3CL protease inhibitor
SARS-CoV-2 viral load
Alleviation of COVID-19 symptoms
Online Access:http://www.sciencedirect.com/science/article/pii/S2666606523001530

Internet

http://www.sciencedirect.com/science/article/pii/S2666606523001530

Similar Items